Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Cooper Health System
mi
from
Franklin Twp, NJ
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Cooper Health System
mi
from
Franklin Twp, NJ
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
A Phase I Trial Of Intravenous Paclitaxel Intraperitoneal Carboplatin And Intraperitoneal Paclitaxel Or Intravenous Docetaxel, Intraperitoneal Carboplatin, And Intraperitoneal Paclitaxel Or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel And CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) In Patients With Previously Untreated Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
One Dose of Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
A Phase I Study of Infusion of HER-2/Neu Specific T-cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
One Dose of Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
A Phase I Study of Infusion of HER-2/Neu Specific T-cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Nevada Cancer Institute
mi
from
Las Vegas, NV
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
mi
from
Las Vegas, NV
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Ohio State University Comprehensive Wound Center
mi
from
Columbus, OH
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
Ohio State University Comprehensive Wound Center
mi
from
Columbus, OH
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
University of Iowa
mi
from
Iowa City, IA
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
University of Iowa
mi
from
Iowa City, IA
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Providence Medical Center
mi
from
Portland, OR
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
Providence Medical Center
mi
from
Portland, OR
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
A Phase I Study of Bevacizumab in Combination With SU11248
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
A Phase I Study of Bevacizumab in Combination With SU11248
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
A Phase I Study of Bevacizumab in Combination With SU11248
Status: Archived
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
A Phase I Study of Bevacizumab in Combination With SU11248
Status: Archived
Updated: 1/1/1970
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Use of Cone Beam Kilovaltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
Evaluation of Cone Beam Kilovoltage Imaging During Radiation Therapy for Tumors of the Head and Neck
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Use of Cone Beam Kilovaltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
Evaluation of Cone Beam Kilovoltage Imaging During Radiation Therapy for Tumors of the Head and Neck
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Sinai-Grace Hospital
mi
from
Detroit, MI
AFP464 in Treating Patients With Advanced Solid Tumors
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sinai-Grace Hospital
mi
from
Detroit, MI
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Rituximab for Prevention of Chronic GVHD
A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Rituximab for Prevention of Chronic GVHD
A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy
Status: Archived
Cancer Treatment Center of America
mi
from
Tulsa, OK
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy
Status: Archived
Updated: 1/1/1970
Cancer Treatment Center of America
mi
from
Tulsa, OK
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Molokai General Hospital
mi
from
Kaunakakai, HI
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Updated: 1/1/1970
Molokai General Hospital
mi
from
Kaunakakai, HI
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Escitalopram in Treating Depression in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Symptom Management Trial in Cancer Survivors
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Escitalopram in Treating Depression in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Symptom Management Trial in Cancer Survivors
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Clearview Cancer Institute
mi
from
Huntsville, AL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Clearview Cancer Institute
mi
from
Huntsville, AL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Florida Cancer Specialists
mi
from
Fort Myers, FL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists
mi
from
Fort Myers, FL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Providence Medical Group
mi
from
Terre Haute, IN
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Providence Medical Group
mi
from
Terre Haute, IN
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
CCOP - Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
CCOP - Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Oncology Hematology Care
mi
from
Cincinnati, OH
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Oncology Hematology Care
mi
from
Cincinnati, OH
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
The Family Cancer Center
mi
from
Collierville, TN
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
The Family Cancer Center
mi
from
Collierville, TN
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI